Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding

PURPOSE: In a phase I trial for patients with refractory solid tumors, hedgehog pathway inhibitor vismodegib (GDC-0449) showed little decline in plasma concentrations over 7 days after a single oral dose and nonlinearity with respect to dose and time after single and multiple dosing. We studied the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Graham, Richard A., Lum, Bert L., Cheeti, Sravanthi, Jin, Jin Yan, Jorga, Karin, Von Hoff, Daniel D., Rudin, Charles M., Reddy, Josina C., Low, Jennifer A., LoRusso, Patricia M.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3703823/
https://ncbi.nlm.nih.gov/pubmed/21300760
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2736
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky